About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00466466

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung c...

Lead sponsor: Novartis Pharmaceuticals•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with histologically or cytologically confirmed diagnosis of extensive disease small-cell lung cancer (ED SCLC)
•Age ≥ 18 years
•WHO Performance Status Grade ≤ 1 (ie. ability to perform normal daily functions)
•Adequate bone marrow, liver and renal function

Exclusion Criteria

•Chronic steroid treatment
•Prior treatment with chemotherapy for advanced lung cancer
•Prior treatment with mTOR inhibitors
•Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections or other severe medical conditions
•Symptomatic or uncontrolled brain metastases
•Other cancers within the past 5 years
•Pregnant or breastfeeding women

Related studies

RECRUITINGPhase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355 · Extensive-stage Small-cell Lung Cancer

RECRUITINGPhase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

RECRUITINGPhase 1/2

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

NCT06217757 · Lung Cancer, Extensive-stage Small-cell Lung Cancer

RECRUITINGPhase 1/2

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

NCT07161388 · Limited Stage Small-Cell Lung Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 21, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment20

Start dateApr 2007

Last updatedDec 21, 2020

Condition

Small-Cell Lung Cancer

Locations shown

Highlands Oncology Group

Fayetteville, Arkansas

University of Colorado Health Sciences Center

Aurora, Colorado

Dana Faber Cancer Institute

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 21, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions